Stock Track | Novo Nordisk Plummets 8.17% Intraday as Hims & Hers Launches Cheaper Wegovy Copycat Pill

Stock Track

Feb 06

Novo Nordisk A/S (NVO) shares plummeted 8.17% during intraday trading on Thursday, as the market reacted to heightened competitive pressure in the lucrative weight-loss drug market.

The sharp decline followed an announcement by telehealth company Hims & Hers Health that it will begin offering compounded copies of Novo Nordisk's Wegovy pill at an introductory price of $49 per month. This represents a significant discount compared to Novo's branded Wegovy, which costs $149 to $299 per month, raising concerns about market share erosion and pricing power for the Danish pharmaceutical giant.

Novo Nordisk responded to the announcement by condemning the move as "illegal mass compounding" that poses risks to patient safety, and stated it would pursue legal and regulatory action against Hims & Hers. The competitive threat was further underscored by BMO Capital Markets lowering its price target on Novo Nordisk shares from $57 to $45, maintaining a Market Perform rating.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1127858583"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1127858583\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1127858583?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-06 04:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1127858583","market":"nz","top_or_hot":-1,"title":"Stock Track | Novo Nordisk Plummets 8.17% Intraday as Hims & Hers Launches Cheaper Wegovy Copycat Pill","media":"Stock Track","content":"<p>Novo Nordisk A/S (NVO) shares plummeted 8.17% during intraday trading on Thursday, as the market reacted to heightened competitive pressure in the lucrative weight-loss drug market.</p><p>The sharp decline followed an announcement by telehealth company Hims & Hers Health that it will begin offering compounded copies of Novo Nordisk's Wegovy pill at an introductory price of $49 per month. This represents a significant discount compared to Novo's branded Wegovy, which costs $149 to $299 per month, raising concerns about market share erosion and pricing power for the Danish pharmaceutical giant.</p><p>Novo Nordisk responded to the announcement by condemning the move as \"illegal mass compounding\" that poses risks to patient safety, and stated it would pursue legal and regulatory action against Hims & Hers. The competitive threat was further underscored by BMO Capital Markets lowering its price target on Novo Nordisk shares from $57 to $45, maintaining a Market Perform rating.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Novo Nordisk Plummets 8.17% Intraday as Hims & Hers Launches Cheaper Wegovy Copycat Pill</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Novo Nordisk Plummets 8.17% Intraday as Hims & Hers Launches Cheaper Wegovy Copycat Pill\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-02-06 04:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Novo Nordisk A/S (NVO) shares plummeted 8.17% during intraday trading on Thursday, as the market reacted to heightened competitive pressure in the lucrative weight-loss drug market.</p><p>The sharp decline followed an announcement by telehealth company Hims & Hers Health that it will begin offering compounded copies of Novo Nordisk's Wegovy pill at an introductory price of $49 per month. This represents a significant discount compared to Novo's branded Wegovy, which costs $149 to $299 per month, raising concerns about market share erosion and pricing power for the Danish pharmaceutical giant.</p><p>Novo Nordisk responded to the announcement by condemning the move as \"illegal mass compounding\" that poses risks to patient safety, and stated it would pursue legal and regulatory action against Hims & Hers. The competitive threat was further underscored by BMO Capital Markets lowering its price target on Novo Nordisk shares from $57 to $45, maintaining a Market Perform rating.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NVO","symbol_name":"诺和诺德","start_time":0,"source_url":"","article_id":"1127858583","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1127858583","pubTimestamp":1770322814,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Novo Nordisk A/S (NVO) shares plummeted 8.17% during intraday trading on Thursday, as the market reacted to heightened competitive pressure in the lucrative weight-loss drug market.The sharp decline...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NVO":"诺和诺德"},"translate_title":"个股追踪|诺和诺德盘中暴跌8.17%，因Hims&Hers推出更便宜的Wegovy山寨药","themeId":"f0fce81d99e7c4115b5691df849cabad","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVO":1},"content_text":"Novo Nordisk A/S (NVO) shares plummeted 8.17% during intraday trading on Thursday, as the market reacted to heightened competitive pressure in the lucrative weight-loss drug market.The sharp decline followed an announcement by telehealth company Hims & Hers Health that it will begin offering compounded copies of Novo Nordisk's Wegovy pill at an introductory price of $49 per month. This represents a significant discount compared to Novo's branded Wegovy, which costs $149 to $299 per month, raising concerns about market share erosion and pricing power for the Danish pharmaceutical giant.Novo Nordisk responded to the announcement by condemning the move as \"illegal mass compounding\" that poses risks to patient safety, and stated it would pursue legal and regulatory action against Hims & Hers. The competitive threat was further underscored by BMO Capital Markets lowering its price target on Novo Nordisk shares from $57 to $45, maintaining a Market Perform rating.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}